Scott Schoenhaus
KeyBanc Capital Markets Inc., Research Division
I guess, Ramy and Richie, maybe walk through for the investors that are new to the story, because a lot has even changed in the last 6 to 12 months about the Schrodinger platform and how you’ve made some changes.
Ramy Farid
CEO, President & Director
Of course. Yes, so I’ll start us off. At the highest level, what our goal is, our mission is to develop a computational platform that allows researchers both in life science companies and in material science companies to design better molecules more rapidly, more efficiently. And that requires developing a platform that can replace experiment because the traditional way of doing drug discovery is by trial and error.
You make a molecule in the lab, you assay it, check its properties. And if it doesn’t have the properties you’re looking for, which, of course, will always be the case when you start off a project, you start to optimize it. So you try to make a change to the molecule. And obviously, that’s very time consuming and prone to huge failure rates, as we all know.
So the whole goal of computationally driven drug discovery materials
Read the full article here
